# Ruxolitinib in the Treatment of Covid-19

> **NCT04414098** · PHASE2 · UNKNOWN · sponsor: **Marcelo Iastrebner** · enrollment: 100 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** INC424 / Ruxolitinib

## Key facts

- **NCT ID:** NCT04414098
- **Lead sponsor:** Marcelo Iastrebner
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2020-08-15
- **Final completion:** 2020-09-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04414098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04414098, "Ruxolitinib in the Treatment of Covid-19". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04414098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*